These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33624165)

  • 1. Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study.
    Ishida T; Yoshida S; Fujiki Y; Hata K; Kotani T; Takeuchi T
    Arch Osteoporos; 2021 Feb; 16(1):39. PubMed ID: 33624165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
    Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A
    J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial.
    Iseri K; Iyoda M; Watanabe M; Matsumoto K; Sanada D; Inoue T; Tachibana S; Shibata T
    PLoS One; 2018; 13(3):e0193846. PubMed ID: 29543887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of denosumab on bisphosphonate-treated osteoporosis and osteopenia in systemic rheumatic disease patients receiving glucocorticoids.
    Tamechika SY; Ohmura SI; Maeda S; Naniwa T
    J Bone Miner Metab; 2023 Mar; 41(2):203-211. PubMed ID: 36512086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis.
    Suzuki T; Nakamura Y; Kato H
    Mod Rheumatol; 2018 Sep; 28(5):885-889. PubMed ID: 29251033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
    Mok CC; Ho LY; Ma KM
    Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
    Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
    Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
    Saag KG; Pannacciulli N; Geusens P; Adachi JD; Messina OD; Morales-Torres J; Emkey R; Butler PW; Yin X; Lems WF
    Arthritis Rheumatol; 2019 Jul; 71(7):1174-1184. PubMed ID: 30816640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Denosumab for Osteoporosis in Patients with Rheumatic Diseases.
    Kaneko K; Shikano K; Kawazoe M; Kawai S; Nanki T
    Intern Med; 2022; 61(16):2405-2415. PubMed ID: 35965073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease.
    Ishiguro S; Ito K; Nakagawa S; Hataji O; Sudo A
    Arch Osteoporos; 2017 Dec; 12(1):44. PubMed ID: 28425086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four-Year Teriparatide Followed by Denosumab
    Hirooka Y; Nozaki Y; Okuda S; Sugiyama M; Kinoshita K; Funauchi M; Matsumura I
    Front Endocrinol (Lausanne); 2021; 12():753185. PubMed ID: 34646240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.
    Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
    Osteoporos Int; 2019 Jan; 30(1):241-249. PubMed ID: 30187112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients.
    Hori M; Yasuda K; Takahashi H; Kondo C; Shirasawa Y; Ishimaru Y; Sekiya Y; Morozumi K; Maruyama S
    Sci Rep; 2022 May; 12(1):7781. PubMed ID: 35546172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D and Calcium Addition during Denosumab Therapy over a Period of Four Years Significantly Improves Lumbar Bone Mineral Density in Japanese Osteoporosis Patients.
    Suzuki T; Nakamura Y; Kato H
    Nutrients; 2018 Feb; 10(3):. PubMed ID: 29495518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis.
    Hasegawa E; Ito S; Takai C; Kobayashi D; Nomura Y; Otani H; Abe A; Ishikawa H; Murasawa A; Narita I; Nakazono K
    Intern Med; 2018 Aug; 57(15):2169-2178. PubMed ID: 29607978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis.
    Yanbeiy ZA; Hansen KE
    Drug Des Devel Ther; 2019; 13():2843-2852. PubMed ID: 31616133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
    Hakala M; Kröger H; Valleala H; Hienonen-Kempas T; Lehtonen-Veromaa M; Heikkinen J; Tuomiranta T; Hannonen P; Paimela L;
    Scand J Rheumatol; 2012 Aug; 41(4):260-6. PubMed ID: 22803768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of denosumab treatment in chronic liver disease patients with osteoporosis.
    Saeki C; Saito M; Oikawa T; Nakano M; Torisu Y; Saruta M; Tsubota A
    World J Gastroenterol; 2020 Sep; 26(33):4960-4971. PubMed ID: 32952342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration.
    Kobayakawa T; Miyazaki A; Kanayama Y; Hirano Y; Takahashi J; Suzuki T; Nakamura Y
    Mod Rheumatol; 2023 Jan; 33(1):96-103. PubMed ID: 35234889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.